Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vepdegestrant tablet versus intravenous infusion pharmacokinetics study in healthy adults
NL-OMON58668Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2025
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of vepdegestrant, sponsored by Pfizer. Started Apr 2025; status: completed.
02
Drugs
vepdegestrant
Beyond the preview
Go deeper on NL-OMON58668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58668.